loading page

Neoadjuvant chemotherapy or upfront surgery in hepatoblastoma: A multicenter retrospective study
  • +6
  • Long Li,
  • Yu Tian,
  • Xinghai Chen,
  • Fan Yu,
  • Jiayi Feng,
  • Guimin Huang,
  • Xianghai Ren,
  • Huimin Hu,
  • Weiling Zhang
Long Li
Capital Institute of Pediatrics-Peking University Teaching Hospital

Corresponding Author:[email protected]

Author Profile
Yu Tian
Capital Institute of Pediatrics-Peking University Teaching Hospital
Author Profile
Xinghai Chen
Capital Institute of Pediatrics-Peking University Teaching Hospital
Author Profile
Fan Yu
China Medical University School of Public Health
Author Profile
Jiayi Feng
Capital Institute of Pediatrics-Peking University Teaching Hospital
Author Profile
Guimin Huang
Capital Institute of Pediatrics
Author Profile
Xianghai Ren
Zhongnan Hospital of Wuhan University Department of Colorectal and Anal Surgery
Author Profile
Huimin Hu
Capital Medical University
Author Profile
Weiling Zhang
Capital Medical University
Author Profile

Abstract

Background: We aimed to retrospectively investigate the role of neoadjuvant chemotherapy in low-risk patients with hepatoblastoma (HB) who underwent curative resection between February 2009 and December 2017. We also verified the feasibility of the risk stratification system to select the optimal patients for upfront resection. Procedure: We compared 5-year overall survival (OS) and event-free survival (EFS) between the upfront surgery (US) (n=26) and neoadjuvant chemotherapy (NC) (n=104) groups at three oncology centers in Beijing, China. To reduce the effect of covariate imbalances, propensity score matching (PSM) was used. We explored whether preoperative chemotherapy affected surgical outcomes and identified the risk factors for events and death, including resection margin status, PRETreatment EXTent of disease stages, age, sex, pathology classification, and α-fetoprotein levels. Results: The median follow-up period was 64 months (interquartile range 60–72). After PSM, 22 pairs of patients were identified and the patient characteristics were similar for all variables included in propensity score matching. In the US group, the 5-year EFS and OS rates were 81.8% and 86.3%, respectively. In the NC group, 5-year EFS and OS rates were 81.8% and 90.9%, respectively. No significant differences in EFS or OS were observed between the groups. Pathological classification was the only risk factor for death and disease progression, tumor recurrence, diagnosis of other malignant neoplasms, and death from any cause ( p=0.007 and p=0.032, respectively). Conclusion: Upfront resection can achieve long-term disease control in low-risk patients with resectable HB, thus reducing the cumulative toxicity of platinum-based chemotherapy drugs.
17 Feb 2023Submission Checks Completed
17 Feb 2023Assigned to Editor
17 Feb 2023Submitted to Pediatric Blood & Cancer
17 Feb 2023Review(s) Completed, Editorial Evaluation Pending
20 Feb 2023Reviewer(s) Assigned
13 Mar 2023Editorial Decision: Revise Major
24 Mar 2023Submission Checks Completed
24 Mar 2023Assigned to Editor
24 Mar 20231st Revision Received
24 Mar 2023Review(s) Completed, Editorial Evaluation Pending
27 Mar 2023Reviewer(s) Assigned
14 Apr 2023Editorial Decision: Revise Major
02 May 2023Submission Checks Completed
02 May 2023Assigned to Editor
02 May 20232nd Revision Received
02 May 2023Review(s) Completed, Editorial Evaluation Pending
02 May 2023Reviewer(s) Assigned
17 May 2023Editorial Decision: Accept